(CIDRAP News) The US government today announced the awarding of three contacts to buy enough additional H5N1 avian influenza vaccine to immunize almost 2.7 million people, at a cost of $199.45 million.
(CIDRAP News) A group of influenza experts convened by the World Health Organization cautioned today that governments shouldn't stockpile "pre-pandemic" H5N1 influenza vaccines now, because too little is known about the requirements for an effective vaccine.
(CIDRAP News) – Low doses of a cell-based avian flu vaccine triggered a good immune response to the H5N1 avian influenza virus, according to preliminary results of a clinical trial by Baxter International of Deerfield, Ill., maker of the vaccine.
(CIDRAP News) The human immune system may respond better to a vaccine for a new strain of H5N1 avian influenza if it is prepared in advance with a vaccine based on an existing H5N1 strain, the preliminary results of a government-sponsored study suggest.
(CIDRAP News) Live-virus vaccines made from a combination of H5N1 avian influenza virus and another flu strain protected laboratory mice and ferrets from deadly infection with several different H5N1 strains, according to a report published yesterday.
Sept 7, 2006 (CIDRAP News) In a human trial in China, a whole-virus H5N1 avian influenza vaccine generated an immune response with a relatively low dose of antigen, suggesting that it could be used to immunize more people than may be possible with some other vaccines under development.
(CIDRAP News) An H5N1 avian influenza vaccine made by GlaxoSmithKline (GSK) triggered a good immune response in human volunteers at a much lower dose than other H5N1 vaccines reported so far, which means that hundreds of millions of doses could be produced by next year, the company announced today.
(CIDRAP news) In a human trial in France, an experimental H5N1 avian influenza vaccine with an adjuvant showed modestly better performance at a lower dose compared with a similar H5N1 vaccine that was tested earlier in the United States.
(CIDRAP News) Health and Human Services (HHS) Secretary Mike Leavitt, reporting this week on preparations for a possible influenza pandemic, promised to act soon to boost US flu vaccine production capacity and promote cell-based vaccine technology.
(CIDRAP News) A second vaccine against human H5N1 influenza is being developed, US Health and Human Services (HHS) Secretary Mike Leavitt announced yesterday.
In a speech at an immunization conference, Leavitt announced that he has authorized the National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC) to start work on a second vaccine, according to an Associated Press (AP) report published yesterday.